Chakravarti To Chair Radiation Medicine DepartmentCOLUMBUS, Ohio – Dr. Arnab Chakravarti (43017) has been recruited as professor and chair of The Ohio State University Department of Radiation Medicine and as a member of the experimental therapeutics program at The Ohio State University Comprehensive Cancer Center. His appointment was approved today (4/3) by Ohio State’s Board of Trustees.
Chakravarti comes to Ohio State from Harvard Medical School, where he was an associate professor and a radiation oncologist at Massachusetts General Hospital (MGH). Chakravarti also was chief of the Brian D. Silber Laboratory of Molecular and Cellular Radiation Oncology at MGH-Harvard. He is bringing at least six cancer researchers and lab technicians with him to Ohio State, in addition to at least four adjunct faculty members from Harvard and around the world. “We look to Dr. Chakravarti to increase basic science and clinical collaborations, resulting in more translational research opportunities across the cancer program and the Center for Clinical and Translational Science,” says Dr. Wiley “Chip” Souba Jr., dean of Ohio State’s College of Medicine, vice president of health sciences and executive dean for Health Sciences. Chakravarti also was named to the Max Morehouse Chair in Cancer Research, which was established in 2000 by Martha Morehouse to honor her father, a local businessman and pioneer in the air cargo industry. The chair supports the work of a nationally eminent faculty member in cancer research. He is principal investigator and chair of the Radiation Therapy and Oncology Group (RTOG) Brain Tumor Translational Research Steering Group and co-chair of the RTOG Brain Tumor Committee. He also is a member of the Translational Research Steering Committee of the RTOG, which is a clinical trials group supported by the National Cancer Institute. He chairs the Scientific Program Committee of the American Society for Therapeutic Radiology and Oncology, serves on the editorial boards of five publications, including Cancer Investigation and Neuro-oncology and the Journal of Neuro-oncology. He is a reviewer for eight other journals including Cancer Research and the Journal of the National Cancer Institute. He has published more than 60 articles and book chapters and has delivered numerous distinguished lectureships in the United States and Europe on the molecular mechanisms of radiation resistance in gliomas and prostate cancer. Chakravarti earned his medical degree from the University of Virginia School of Medicine. He served as resident and chief resident in Radiation Oncology at the Harvard Medical School – Massachusetts General Hospital. The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute is one of only 40 NCI-designated Comprehensive Cancer Centers in the United States and the only freestanding cancer hospital in the Midwest. Ranked among the top 20 cancer hospitals in the nation, The James is the 172-bed adult patient-care component of the cancer program at The Ohio State University.
|
